{"log_id": 4484827995404433666, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0.000756, "average": 0.990182, "min": 0.877787}, "location": {"width": 777, "top": 211, "height": 30, "left": 235}, "words": "究中,6个月后缓释胶囊组和安慰剂组分别有3%和1%的患者体重下降超过7%。随访至8周"}, {"probability": {"variance": 5.3e-05, "average": 0.995846, "min": 0.970903}, "location": {"width": 423, "top": 258, "height": 27, "left": 232}, "words": "时有0.3%服用本品的GAD患者因为体重下降停药"}, {"probability": {"variance": 0.000148, "average": 0.99269, "min": 0.940434}, "location": {"width": 735, "top": 301, "height": 31, "left": 278}, "words": "文拉法辛合并减肥药(如芬特明)的疗效和安全性尚未明确,建议不合并使用文拉法辛"}, {"probability": {"variance": 0.006516, "average": 0.982675, "min": 0.571168}, "location": {"width": 532, "top": 347, "height": 30, "left": 235}, "words": "和减肥药。文拉法辛也未批准单独或合并用于降低体重的治疗"}, {"probability": {"variance": 4.6e-05, "average": 0.994771, "min": 0.985205}, "location": {"width": 26, "top": 319, "height": 77, "left": 1159}, "words": "一监证"}, {"probability": {"variance": 4e-06, "average": 0.998641, "min": 0.994443}, "location": {"width": 100, "top": 396, "height": 24, "left": 270}, "words": "食欲的变化"}, {"probability": {"variance": 7e-06, "average": 0.998739, "min": 0.984802}, "location": {"width": 731, "top": 435, "height": 32, "left": 283}, "words": "成年患者:通过对短程、双盲和安慰剂对照治疗抑郁症的研究的汇总分析,本品缓释"}, {"probability": {"variance": 0.001625, "average": 0.989371, "min": 0.751511}, "location": {"width": 779, "top": 481, "height": 32, "left": 235}, "words": "胶囊治疗组比安慰剂组有更多的患者出现厌食,分别达到8%和4%。治疗抑郁症的过程中有"}, {"probability": {"variance": 0.000229, "average": 0.993854, "min": 0.923392}, "location": {"width": 765, "top": 527, "height": 30, "left": 241}, "words": "1%的患者因为厌食停用本品。通过对短程、双盲和安慰剂对照治疗GAD的研究的汇总分析"}, {"probability": {"variance": 1.4e-05, "average": 0.998315, "min": 0.977948}, "location": {"width": 762, "top": 570, "height": 32, "left": 236}, "words": "在本品治疗组比安慰剂组有更多的患者出现厌食,分别达到8%和2%,在8周的治疗期内"}, {"probability": {"variance": 6.5e-05, "average": 0.995321, "min": 0.964202}, "location": {"width": 325, "top": 619, "height": 24, "left": 238}, "words": "有0.9%的GAD患者因为厌食停用本品"}, {"probability": {"variance": 0.006049, "average": 0.970216, "min": 0.764446}, "location": {"width": 146, "top": 664, "height": 25, "left": 271}, "words": "诱发躁狂/轻躁狂"}, {"probability": {"variance": 0.000638, "average": 0.99139, "min": 0.847252}, "location": {"width": 733, "top": 703, "height": 32, "left": 285}, "words": "上市前的临床研究显示:用于治疗抑郁症时,有0.3%的服用本品缓释胶囊的患者出现"}, {"probability": {"variance": 0.000347, "average": 0.991787, "min": 0.898787}, "location": {"width": 771, "top": 749, "height": 32, "left": 236}, "words": "躁狂或轻躁狂,安慰剂组为0%;用于治疗GAD时,服用本品患者无一出现躁狂或轻躁狂"}, {"probability": {"variance": 6.3e-05, "average": 0.996878, "min": 0.953325}, "location": {"width": 762, "top": 793, "height": 32, "left": 237}, "words": "安慰剂组躁狂或轻躁狂发生率为0.2%。在所有的文拉法辛常释制剂治疗抑郁症的研究中"}, {"probability": {"variance": 0.000553, "average": 0.99066, "min": 0.886574}, "location": {"width": 779, "top": 838, "height": 32, "left": 239}, "words": "患者中有0.5%发生躁狂或轻躁狂,而安慰剂组却未发生。据报道已上市的抗抑郁药物(包"}, {"probability": {"variance": 4.5e-05, "average": 0.997145, "min": 0.963432}, "location": {"width": 768, "top": 883, "height": 30, "left": 239}, "words": "括文拉法辛)治疗抑郁症时也有少数的患者出现躁狂或轻躁狂。和所有的抗抑郁药物一样"}, {"probability": {"variance": 5.5e-05, "average": 0.996713, "min": 0.964972}, "location": {"width": 414, "top": 931, "height": 26, "left": 241}, "words": "本品慎用于有双相情感障碍病史或家族史的患者"}, {"probability": {"variance": 3e-06, "average": 0.996073, "min": 0.994335}, "location": {"width": 102, "top": 978, "height": 23, "left": 275}, "words": "攻击性行为"}, {"probability": {"variance": 0.004054, "average": 0.973649, "min": 0.702653}, "location": {"width": 733, "top": 1015, "height": 33, "left": 286}, "words": "曾经接受抗抑郁药物治疗(包括文拉法辛的治疗,降低剂量和中断治疗)数患者可"}, {"probability": {"variance": 0.01456, "average": 0.95417, "min": 0.46935}, "location": {"width": 761, "top": 1059, "height": 33, "left": 240}, "words": "能发生攻击性行为。与使用其它抗抑郁药物类似,对于具有攻击性向病史的患者便用文"}, {"probability": {"variance": 3.4e-05, "average": 0.996631, "min": 0.983765}, "location": {"width": 121, "top": 1111, "height": 25, "left": 241}, "words": "法辛需要谨慎"}, {"probability": {"variance": 3e-06, "average": 0.998274, "min": 0.995764}, "location": {"width": 83, "top": 1154, "height": 25, "left": 275}, "words": "低钠血症"}, {"probability": {"variance": 0.017079, "average": 0.951494, "min": 0.471712}, "location": {"width": 737, "top": 1194, "height": 28, "left": 283}, "words": "通常在低血容量或者脱水患者中,使用SSRI和 SNRIS药物包括文拉法辛时可能发低"}, {"probability": {"variance": 0.003862, "average": 0.986669, "min": 0.605503}, "location": {"width": 777, "top": 1237, "height": 32, "left": 242}, "words": "钠血症和或抗利尿激素分泌异常综合征。老年患者、服用利尿剂的患者和由于其他原因导"}, {"probability": {"variance": 0.000447, "average": 0.994068, "min": 0.865241}, "location": {"width": 779, "top": 1281, "height": 33, "left": 242}, "words": "致的低血容量者,有较大的风险出现低钠血症。在大多数情况下,低钠血症是由于抗利尿素"}, {"probability": {"variance": 0.000472, "average": 0.988108, "min": 0.912664}, "location": {"width": 531, "top": 1328, "height": 31, "left": 242}, "words": "分泌异常综合征( SIADH)引起的。有病例报道血清钠低于11"}, {"probability": {"variance": 0.00181, "average": 0.982464, "min": 0.855769}, "location": {"width": 193, "top": 1328, "height": 23, "left": 826}, "words": "L。对于出现低钠血症"}, {"probability": {"variance": 0.011719, "average": 0.974572, "min": 0.434979}, "location": {"width": 514, "top": 1373, "height": 30, "left": 243}, "words": "症状的患者应考虑停用本品,并采取合适的医学干预措施"}, {"probability": {"variance": 3.3e-05, "average": 0.997808, "min": 0.964924}, "location": {"width": 737, "top": 1416, "height": 31, "left": 284}, "words": "低钠血症的症状包括头痛、思想集中困难、记忆损伤、意识模糊、虚弱、可能导致跌倒"}, {"probability": {"variance": 0.000155, "average": 0.995383, "min": 0.930159}, "location": {"width": 728, "top": 1460, "height": 34, "left": 243}, "words": "的摇摆不定。严重或急性的症状包括幻觉、晕厥、癫痫发作、昏迷、呼吸停止和死亡"}, {"probability": {"variance": 2e-06, "average": 0.998243, "min": 0.996687}, "location": {"width": 42, "top": 1512, "height": 22, "left": 278}, "words": "惊厥"}], "language": 3}